Biography
Sharon Tetlow is a seasoned Audit Committee Chair in the Life Sciences Industry specializing in transition from private to public, and from 404a to 404b stage companies. As AC chair she has 3 NASDAQ IPOs and two successful acquisitions. Known for leadership in fundraising strategies, business growth and financial compliance, Ms. Tetlow is a trusted partner to boards and CEOs to help optimize strategic outcomes. She currently serves as board member, audit committee chair, qualified financial expert and nomination and governance committee member for Structure Therapeutics (GPCR:NASDAQ), a multinational, clinical stage life sciences company with headquarters in South San Francisco CA. She was previously board member, audit committee chair, qualified financial expert and nomination and governance committee member for Dice Therapeutics (DICE:NASDAQ) beginning prior to its highly successful IPO until it was purchased by Eli Lilly in August 2023. She also served on the supervisory board of directors and as audit committee chair of Valneva SE, a global, commercial stage, life sciences company (VALN:NASDAQ and VLA.PA Euronext Paris) headquartered in France from before its NASDAQ IPO until December 2023 and as board member, financial expert, transaction committee member and audit committee chair for Catalyst Bio (CBIO:NASDAQ) until its merger in December 2022. Ms. Tetlow also serves on the board of Cessation Therapeutics, a private clinical stage company in the anti-opioid therapeutics space and has served on several not-for-profit boards over the past twenty years. Prior to her corporate board work, Ms. Tetlow served as CFO of multiple biotech companies and founded and still leads Potrero Hill Advisors, LLC, a company providing CFO and financial support to biotech companies. Ms. Tetlow received her MBA from Stanford University’s Graduate School of Business in 1986 and her BS from University of Delaware in 1981.
